ApoLife

ApoLife is a privately held biotechnology company focused on developing a technology platform based on a proprietary yeast (S. cerevisiae) expression system, which can accelerate the discovery and development of antibody therapies and recombinant proteins. ApoLife has successfully secured grants from the U.S. National Institutes of Health and the Michigan Economic Development Corporation, providing third-party validation for its technology. The company has utilized these funds to develop platform technology, intellectual property, and technical know-how to advance and engage in the rapidly expanding market for therapeutic recombinant proteins, monoclonal antibodies (mAbs), next-generation antibody scaffolds, and biosimilar products including recombinant vaccines. The company employs Saccharomyces cerevisiae, which has already been used in the production of several FDA-approved therapeutic products, thereby offering a competitive regulatory advantage over other yeast expression systems. By applying ApoLife's proprietary Twin Cassette® expression system, biopharma and biotech companies can expedite the process of bringing new therapies to market and help reduce healthcare costs.